Literature DB >> 34345999

Autophagy in Xp11 translocation renal cell carcinoma: from bench to bedside.

Huimin Sun1, Xing Wei2, Changchun Zeng3.   

Abstract

Xp11 translocation renal cell carcinoma (tRCC) characterized by the rearrangement of the TFE3 is recently identified as a unique subtype of RCC that urgently requires effective prevention and treatment strategies. Therefore, determining suitable therapeutic targets and fully understanding the biological significance of tRCC is essential. The importance of autophagy is increasingly acknowledged because it shows carcinogenic activity or suppressor effect. Autophagy is a physiological cellular process critical to maintaining cell homeostasis, which is involved in the lysosomal degradation of cytoplasmic organelles and macromolecules via the lysosomal pathway, suggesting that targeting autophagy is a potential therapeutic approach for cancer therapies. However, the underlying mechanism of autophagy in tRCC is still ambiguous. In this review, we summarize the autophagy-related signaling pathways associated with tRCC. Moreover, we examine the roles of autophagy and the immune response in tumorigenesis and investigate how these factors interact to facilitate or prevent tumorigenesis. Besides, we review the findings regarding the treatment of tRCC via induction or inhibition of autophagy. Hopefully, this study will shed some light on the functions and implications of autophagy and emphasize its role as a potential molecular target for therapeutic intervention in tRCC.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Autophagy; Mechanism; TFE3; Therapy; Xp11 translocation renal cell carcinoma

Mesh:

Substances:

Year:  2021        PMID: 34345999     DOI: 10.1007/s11010-021-04235-w

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  87 in total

Review 1.  MiT family translocation renal cell carcinomas: A 15th anniversary update.

Authors:  Jatin S Gandhi; Faizan Malik; Mahul B Amin; Pedram Argani; Armita Bahrami
Journal:  Histol Histopathol       Date:  2019-09-06       Impact factor: 2.303

Review 2.  Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.

Authors:  Anna Caliò; Matteo Brunelli; Diego Segala; Serena Pedron; Andrea Remo; Serena Ammendola; Enrico Munari; Francesco Pierconti; Alessandra Mosca; Enrico Bollito; Angelo Sidoni; Simona Fisogni; Cosimo Sacco; Luisa Canu; Steno Sentinelli; Anna Paola Fraccon; Michelangelo Fiorentino; Cathryn Scott; Michele Milella; Camillo Porta; Pedram Argani; Guido Martignoni
Journal:  Pathology       Date:  2020-02-24       Impact factor: 5.306

3.  Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review.

Authors:  Toshihiko Masago; Susumu Kobayakawa; Yuu Ohtani; Kenjirou Taniguchi; Takuji Naka; Naoto Kuroda; Chihiro Takahashi; Tadahiro Isoyama; Takehiro Sejima
Journal:  Int Cancer Conf J       Date:  2020-07-08

Review 4.  Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.

Authors:  Eric C Kauffman; Christopher J Ricketts; Soroush Rais-Bahrami; Youfeng Yang; Maria J Merino; Donald P Bottaro; Ramaprasad Srinivasan; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2014-07-22       Impact factor: 14.432

5.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

6.  Genomic heterogeneity of translocation renal cell carcinoma.

Authors:  Gabriel G Malouf; Federico A Monzon; Jérôme Couturier; Vincent Molinié; Bernard Escudier; Philippe Camparo; Xiaoping Su; Hui Yao; Pheroze Tamboli; Dolores Lopez-Terrada; Maria Picken; Marileila Garcia; Asha S Multani; Sen Pathak; Christopher G Wood; Nizar M Tannir
Journal:  Clin Cancer Res       Date:  2013-07-01       Impact factor: 12.531

Review 7.  Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.

Authors:  Carla L Ellis; John N Eble; Andrea P Subhawong; Guido Martignoni; Minghao Zhong; Marc Ladanyi; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Mod Pathol       Date:  2013-12-06       Impact factor: 7.842

8.  RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.

Authors:  Xiao-Tong Wang; Qiu-Yuan Xia; Sheng-Bing Ye; Xuan Wang; Rui Li; Ru Fang; Shan-Shan Shi; Ru-Song Zhang; Xiao Tan; Jie-Yu Chen; Ke Sun; Xiao-Dong Teng; Heng-Hui Ma; Zhen-Feng Lu; Xiao-Jun Zhou; Qiu Rao
Journal:  Mod Pathol       Date:  2018-04-30       Impact factor: 7.842

Review 9.  Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.

Authors:  Xiangming Cheng; Weidong Gan; Gutian Zhang; Xiaogong Li; Hongqian Guo
Journal:  BMC Urol       Date:  2016-07-11       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.